Related Experiment Videos

Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis

I Torsteinsdóttir1, L Hâkansson, R Hällgren

  • 1Department of Medical Sciences, Clinical Chemistry and Rheumatology, University Hospital, Uppsala, Sweden.

Abstract

Insights

Serum lysozyme and myeloperoxidase (MPO) levels are elevated in rheumatoid arthritis (RA) patients, indicating increased monocyte/macrophage activity. These markers may help monitor RA disease activity.

Area of Science:

  • Immunology
  • Rheumatology
  • Biochemistry

Background:

  • Rheumatoid arthritis (RA) involves complex immune dysregulation.
  • Monocytes and macrophages are key cellular players in RA pathogenesis.
  • Biomarkers reflecting mononuclear phagocyte activity are needed for RA assessment.

Purpose of the Study:

  • To estimate the contribution of monocytes/macrophages to rheumatoid arthritis (RA).
  • To measure serum levels of leucocyte-derived granular proteins: lysozyme, myeloperoxidase (MPO), lactoferrin, and human neutrophil lipocalin (HNL) in RA patients.
  • To assess the impact of prednisolone and metyrapone on these markers.

Main Methods:

  • Serum granular protein levels were quantified in 23 RA patients and 27 healthy controls.
  • Measurements were repeated in 10 RA patients after prednisolone treatment.
  • Serum levels were also assessed before and after metyrapone administration.

Main Results:

  • Serum lysozyme and MPO concentrations were significantly elevated in RA patients compared to controls.
  • Lactoferrin and HNL levels did not differ between groups.
  • Prednisolone treatment led to a decrease in serum lysozyme and MPO levels.

Conclusions:

  • Elevated serum lysozyme and MPO in RA suggest stimulated secretory activity of mononuclear phagocytes.
  • Serum lysozyme may serve as a potential indicator of monocyte/macrophage activity in RA.
  • Further research can explore these markers for monitoring RA disease activity.

Related Concept Videos